Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Phase 3
Terminated
- Conditions
- Acromegaly
- Interventions
- Drug: C2L-OCT-01 PR, 20 mgDrug: C2L-OCT-01 PR, 10 or 20 mg
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00642421
- Locations
- πΊπΈ
The Cleveland Clinic, Cleveland, Ohio, United States
πΊπΈUCLA Medical Center Division of Neurosurgery, Los Angeles, California, United States
πΊπΈStanford University Medical Center, Stanford, California, United States
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Phase 3
Completed
- Conditions
- Acromegaly
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00635765
- Locations
- π§πΎ
Republican Centre for Medical Rehabilitation and Water-therapy, Minsk, Belarus
π·π΄Institue of Endocrinology "C.I Parhon" Bucharest, Bucharest, Romania
ππΊSemmelweis Egyetem Altalanos Orvostudomanyi, Budapest, Hungary
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
Phase 3
Completed
- Conditions
- Acromegaly
- Interventions
- Drug: C2L-OCT-01 PR, 30 mg
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00616551
- Locations
- πΊπ¦
V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine, Kiev, Ukraine
π§πΎRepublican Centre for Medical Rehabilitation and Water-therapy, Minsk, Belarus
π·π΄Institute of Endocrinology "C. I. Parhon" Bucharest, Bucharest, Romania
Β© Copyright 2025. All Rights Reserved by MedPath